MedPath

RANDOMIZED CONTROLLED TRIAL OF THE EFFECTS OF PARENTERAL FISH OIL EMULSION IN CRITICALLY ILL SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT

Phase 1
Conditions
Sepsis
Registration Number
EUCTR2009-016880-13-GB
Lead Sponsor
IVERSITY HOSPITALS OF LEICESTER NHS TRUST
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
74
Inclusion Criteria

All critically Ill septic patients in the intensive care unit between age 18 and 90 and without exclusion criteria.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

The following will be excluded from the trial:
•Planned ITU/HDU admission post elective surgery.
•Hypersensitivity to fish, egg or soy protein.
•Uncontrolled hyperlipidaemia
•Severe primary blood coagulation disorder
•Acute pancreatitis accompanied with hyperlipidaemia
•Ketoacidosis
•Acute thromboembolic disease
•Severe liver failure
•Acute phase of myocardial infarction or stroke
•Pregnancy

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: The effect of Omega 3 fatty acids on reduction of APACHE II score as a surrogate marker of mortality.;Secondary Objective: • Progression of care from level 2 to level3<br>• Down staging of care from level 3 to level 2, or level 2 to level 1<br>• Mortality rate<br>• Length of hospital stay<br>• Time intubated<br>• Inotrope requirements<br>• Organ support (filter)<br>• Return to pre-morbid function<br>• Changes in inflammatory makers C-reactive protein, White Blood Cell Count (WBC), total protein/albumin<br>• Measured ?-3/6 FA levels and ratios in cellular membranes of blood leukocytes to confirm uptake<br>• Change in serum leucotrienes, pAF, interleukin, PGE2, LT-4, TNFa, IL-1 and IL6. Plus other inflammatory markers;Primary end point(s): Lowering APACHE II score
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath